32 research outputs found
Intrahepatic Cholangiocarcinoma: Clinical Aspects, Pathology and Treatment
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary tumor of the liver. To
further define its clinicopathology and surgical management, we reviewed our experience. Clinical
presentations of 32 patients with ICC was similar to that with hepatocellular carcinoma. Jaundice
occurred in only 27 percent. ICC was unresectable due to advanced disease stage in 81 percent. Six
patients had curative resections with two 5 year disease free survivors. Underlying liver disease was
associated with ICC in 34 percent of patients
Are Concomitant Surgical Procedures Acceptable in Patients Undergoing Cervical Exploration for Primary Hyperparathyroidism?
Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma
The proven power of DNA ploidy to predict mortality risk in medullary thyroid carcinoma (MTC) may be weakened when analyzed in conjunction with calcitonin immunoreactivity (CI) and amyloid staining (AS) of tumors. In this study 12 prognostic variables, including DNA ploidy, CI, and AS, were studied in 65 patients with MTC (57 sporadic; mean age 51 years) treated during 1946 through 1970. Cause-specific mortality rates at 10 and 15 years were 15% and 26%, respectively. By univariate analysis, TNM stages III or IV (p < 0.0001), tumor unresectability (p < 0.0001), male sex (p = 0.019), negative AS (p = 0.032), and low CI (p = 0.033) were significant predictors of increased mortality rates. DNA ploidy (p = 0.058) and inheritance pattern (p = 0.25) were nonsignificant. By multivariate analysis, only TNM stage, tumor resectability, and AS were independently significant (p < 0.005). A prognostic model was created, based on presence or absence of these independent risk factors, and four risk groups were defined, capable of predictably defining mortality rates in MTC (p < 0.0001). The model requires validation in larger series and independent verification by others. However, we believe that a risk-group scheme for MTC based on AS, disease stage, and completeness of tumor resection may have wide applicability and prove relevant to clinicians treating this disease